According to the Zhitong Finance App, China Biotech Service (08037) announced its 2023 results, with revenue of approximately HK$212 million, gross profit of HK$343.24 million, and loss of HK$954.47 million for the company owner.

According to the announcement, the loss was mainly due to a decline in demand for the Group's COVID-19 nucleic acid testing services and a decline in sales related to rapid antigen test kits after the relevant government authorities relaxed and later lifted COVID-19 quarantine regulations.